Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Cagrilintide on Oral Contraceptive PK in Overweight/Obese Females
NCT04074174Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cagrilintide in obesity and Overweight, sponsored by Novo Nordisk. Primary endpoints: Area under the ethinylestradiol concentration-time curve (0-24h) at steady state at Day 79 and Area under the levonorgestrel concentration-time curve (0-24h) at steady state at Day 79. Started Sep 2019; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04074174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074174.